• Chardan initiated coverage with a Buy rating and a $20 price target on July 27, sparking investor interest.
  • The company is also set to host a webinar today, July 28, at 8:00 am ET, to discuss 6-month blinded interim data from its PRECISE-AD Phase 1b trial of PMN310 for Alzheimer's disease.
  • ProMIS Neurosciences is trading at $13.57 (15.8% up) in pre-market, driven by this positive sentiment.